Skip to main content

Table 1 The clinicopathological characteristics of patients with resected T1-3N0 − 2 M0 NSCLC

From: RNSCLC-PRSP software to predict the prognostic risk and survival in patients with resected T1-3N0–2 M0 non-small cell lung cancer

Characteristics

Number of patients

All patients

6886 (100%)

Gender

 Male

3363 (48.8%)

 Female

3523 (51.2%)

Age

 ≤65

2964 (43.0%)

 > 65

3922 (57.0%)

Laterality

 Right

3958 (57.5%)

 Left

2928 (42.5%)

Race

 White

5770 (83.8%)

 Black

589 (8.6%)

 Others

527 (7.6%)

N stage a

 N0

4578 (66.5%)

 N1

1228 (17.8%)

 N2

1080 (15.7%)

NELNs

 N ≤ 6

2495 (36.2%)

 6<N ≤ 12

2272 (33.0%)

 N>12

2119 (30.8%)

NPLNs

 N = 0

4658 (67.6%)

 1 ≤ N ≤ 3

1623 (23.6%)

 N ≥ 4

605 (8.8%)

Surgery type

 SLET

599 (8.7%)

 LET

5748 (83.5%)

 PET

539 (7.8%)

Primary site

 UL

4125 (60.0%)

 ML

414 (6.0%)

 LL

2213 (32.1%)

 Others

134 (1.9%)

Histological grade

 I

816 (11.9%)

 II

3158 (45.9%)

 III

2766 (40.2%)

 IV

146 (2.0%)

Histology

 AC

3013 (43.8%)

 S

1629 (23.7%)

 ASC

206 (3.0%)

 BAA

220 (3.2%)

 Others

1818 (26.3%)

Marital status

 Single (never married)

801 (11.6%)

 Married

4115 (59.8%)

 Divorced

854 (12.4%)

 Widowed

1017 (14.8%)

 Others

99 (1.4%)

Tumor extension a

 T1a ss

729 (10.6%)

 T2 Visc PI

4078 (59.2%)

 T2 Centr

1366 (19.8%)

 T3 Inv

68 (1.0%)

 T3 Satell

645 (9.4%)

Tumor size a

 T1a ≤ 1(T ≤ 1)

193 (2.8%)

 T1b>1–2(1<T ≤ 2)

1573 (22.8%)

 T1c>2–3(2<T ≤ 3)

1932 (28.1%)

 T2a>3–4(3<T ≤ 4)

1449 (21.0%)

 T2b>4–5(4<T ≤ 5)

865 (12.6%)

 T3>5–7(5<T ≤ 7)

874 (12.7%)

Survival status

 Dead

2443 (35.5%)

 Alive

4443 (64.5%)

  1. Abbreviations: NELNs Number of examined regional lymph nodes, NPLNs Number of positive regional lymph nodes, SLET sublobectomy, LET Lobectomy, PET Pneumonectomy, UL Upper lobe, ML Middle lobe, LL Lower lobe, I Well differentiated, II Moderately differentiated, III Poorly differentiated, IV Undifferentiated, AC Adenocarcinoma, S Squamous carcinoma, ASC Adenosquamous carcinoma, BAA Bronchioalveolar adenocarcinoma
  2. a According to the eighth edition of the AJCC/UICC stage classification for NSCLC